Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961792 | 1.00 | CTSB (0.56) | CTSBCTSSCTSKCYP3A4ITGB3 | |
| SCHEMBL10799441 | 0.93 | CTSL (0.57) | CTSBCTSSCTSKTACR1CTSL | |
| SCHEMBL27509817 | 0.89 | ITGB3 (0.55) | CTSBCTSSCTSKCYP3A4ITGB3 | |
| SCHEMBL9034586 | 0.89 | ITGB3 (0.49) | CTSBCTSSCTSKCYP3A4ITGB3 | |
| SCHEMBL6781311 | 0.86 | CTSK (0.58) | CTSBCTSSCTSKCYP3A4TACR1 | |
| SCHEMBL5227251 | 0.85 | CTSK (0.57) | CTSBCTSSCTSKCYP3A4ITGB3 | |
| SCHEMBL220648 | 0.83 | TACR1 (0.68) | CTSBCTSSCTSKITGB3ITGA2B | |
| SCHEMBL219151 | 0.83 | TACR1 (0.68) | CTSBCTSSCTSKITGB3ITGA2B | |
| SCHEMBL7372270 | 0.83 | TACR1 (0.68) | CTSBCTSSCTSKITGB3ITGA2B | |
| SCHEMBL479010 | 0.83 | TACR1 (0.68) | CTSBCTSSCTSKITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015095227-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-7767811-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060293536-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2006-12-28 | — | — | US | disclosed |
| US-7057038-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1419125-A4 | KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | UNIV BRANDEIS (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050020849-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | DENG LI (US) | 2005-01-27 | — | — | US | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| US-5734057-A | VIRICIDE | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5624934-A | PREVENTING HIV INFECTION | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| CN-1145587-A | Protease inhibitors | LILLY CO ELI (US) | 1997-03-19 | — | — | CN | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5480887-A | FOR HIV, THIENO(3,2-C)PYRIDINE-(6S)-CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-5312826-A | Dicarboxylic acids with hypotensive agents and cardiovascular disorders | TANABE SEIYAKU CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| EP-0519738-A1 | Dicarboxylic acid derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020849-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | CTSB 3610/4885CTSS 2559/4885CTSK 3365/4885 |
| US-20060293536-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | CTSB 3610/4885CTSS 2559/4885CTSK 3365/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | CTSB 726/4885CTSS 1649/4885CTSK 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.